Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cervical fusion & disc arthroplasty cases in Arizona: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 6% on average (210 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 30 | 1,190 | 44% |
| 2020 | 28 | 1,219 | 46% |
| 2021 | 29 | 1,219 | 49% |
| 2022 | 29 | 1,231 | 51% |
| 2023 | 35 | 1,311 | 53% |
| 2024 | 36 | 1,337 | 54% |
| 2025 from claims | – | 1,428 1,310–1,511 | 55% |
| 2026 forecast | – | 1,489 1,310–1,719 | 55% |
| 2027 forecast | – | 1,547 1,323–1,844 | 56% |
| 2028 forecast | – | 1,608 1,341–1,968 | 56% |
| 2029 forecast | – | 1,670 1,364–2,094 | 57% |
| 2030 forecast | – | 1,734 1,390–2,223 | 57% |
ACDF, posterior cervical fusion, cervical total disc replacement. Professional codes (what the surgeon bills): CPT 22551, 22600, 22856; the hospital bills MS-DRG 471, 472, 473, 429, 430.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 39% of the cases CMS names in Arizona; 26 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 66% inpatient hospital, 28% hospital outpatient, 6% surgery center. The share outside the hospital has moved +3 pts since 2019, so more of this market is decided in surgery centers and offices each year.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 77 | 3,603−4%/yr | −4%/yr | 1.0 | 0% | 4,270 in 2030+2.9%/yr |
| Colorado | 24 | 1,147−1.6%/yr | −1.6%/yr | 2.3 | 1% | 1,280 in 2030+1.9%/yr |
| Washington | 12 | 886−6.9%/yr | −6.9%/yr | 1.1 | 11% | 890 in 20300%/yr |
| Oregon | 11 | 615−5.6%/yr | −5.6%/yr | 1.4 | 25% | 690 in 2030+2%/yr |
| Utah | 9 | 439−3.4%/yr | −3.4%/yr | 1.9 | 17% | 560 in 2030+4.1%/yr |
| Nevada | 3 | 378−6.4%/yr | −6.4%/yr | 1.3 | 0% | 370 in 2030−0.3%/yr |
| Idaho | 8 | 341−3.9%/yr | −3.9%/yr | 1.6 | 0% | 450 in 2030+4.8%/yr |
| Montana | 4 | 238−0.9%/yr | −0.9%/yr | 1.2 | 0% | 270 in 2030+2.1%/yr |
| Alaska | 5 | 221+8.1%/yr | +8.1%/yr | 1.8 | 0% | 400 in 2030+10%/yr |
| New Mexico | 2 | 123−6.5%/yr | −6.5%/yr | 0.5 | 0% | 250 in 2030+13%/yr |
| Wyoming | 2 | 111−8.1%/yr | −8.1%/yr | 1.0 | 0% | 160 in 2030+6.2%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Lumbar fusion | 68 | 2,849+1.1%/yr | +1.1%/yr | 3.71.3× | 2% | 3,400 in 2030+3%/yr |
| Decompression & minimally invasive spine | 72 | 2,815−4.4%/yr | −4.4%/yr | 3.71.2× | 14% | 3,290 in 2030+2.6%/yr |
| Kyphoplasty & vertebroplasty | 15 | 1,110+2.9%/yr | +2.9%/yr | 1.51.8× | 90% | 1,600 in 2030+6.3%/yr |
| SI joint fusion | 5 | 365+24%/yr | +24%/yr | 0.42.2× | 67% | 950 in 2030+17%/yr |
Cervical fusion & disc arthroplasty in every state, and its device makers · Every procedure market in Arizona · Every state · Compare with California
Centinel Spine leads with 39% of company spending on these surgeons in 2025, +27 pts on 2024.
In 2025, 17 companies reported engagement with Arizona’s surgeons worth $384K in consulting, speaking, meals and travel tied to these products, about $11K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 69 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.